We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $581M
1-Year Est. Return 373.68%
This Fund
S&P 500
This Quarter Est. Return
+35.11%
1 Year Est. Return
+373.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$58.2M
Cap. Flow
-$54.7M
Cap. Flow %
-9.43%
Top 10 Hldgs %
40.99%
Holding
116
New
34
Increased
19
Reduced
30
Closed
32

Top Buys

Rank Stock Value
1
TNGX icon
Tango Therapeutics
TNGX
+$25.3M
2
ERAS icon
Erasca
ERAS
+$19M
3
TYRA icon
Tyra Biosciences
TYRA
+$14.5M
4
TRAX
First Tracks Biotherapeutics
TRAX
+$11.6M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$10.9M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$38.5M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$28.4M
3
RVMD icon
Revolution Medicines
RVMD
+$17.8M
4
MBX
MBX Biosciences
MBX
+$14.9M
5
IMVT icon
Immunovant
IMVT
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.23%
2 Miscellaneous 0.45%
3 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NRIX icon
101
Nurix Therapeutics
NRIX
$2.66B
– –
-315,226
Closed -$4.89M
OLMA icon
102
CALL
Olema Pharmaceuticals
OLMA
$938M
– –
-25,000
Closed -$3.75K
PCVX icon
103
Vaxcyte
PCVX
$9.13B
– –
-59,061
Closed -$3.43M
QQQ icon
104
CALL
Invesco QQQ Trust
QQQ
$488B
– –
-40,000
Closed -$74.2K
SNDX icon
105
CALL
Syndax Pharmaceuticals
SNDX
$1.85B
– –
-150,000
Closed -$90K
SNDX icon
106
Syndax Pharmaceuticals
SNDX
$1.85B
– –
-1,215,743
Closed -$28.4M
FTH
107
Faeth Therapeutics
FTH
$1.06B
– –
-132,873
Closed -$4.19M
SPY icon
108
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$816B
– –
-50,000
Closed -$85.5K
SRRK icon
109
CALL
Scholar Rock
SRRK
$6.72B
– –
-100,000
Closed -$588K
STRO icon
110
Sutro Biopharma
STRO
$338M
– –
-23,295
Closed -$580K
TERN
111
CALL
DELISTED
Terns Pharmaceuticals
TERN
– –
-100,000
Closed -$7.5K
TWST icon
112
Twist Bioscience
TWST
$8.27B
– –
-43,110
Closed -$2.05M
TYRA icon
113
CALL
Tyra Biosciences
TYRA
$1.7B
– –
-100,000
Closed -$290K
XFOR icon
114
X4 Pharmaceuticals
XFOR
$402M
– –
-850,742
Closed -$3.51M
MBX
115
MBX Biosciences
MBX
$2.95B
– –
-499,469
Closed -$14.9M
EVMN
116
Evommune Inc
EVMN
$441M
– –
-193,777
Closed -$4.39M
1 2 3 4
5

Similar funds

PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
Cambridge Advisors Omaha, Nebraska $582M AUM 19.14% 1-Year Est. Return

Stempoint Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Stempoint Capital held 116 positions worth $581M, up 11% from $522M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Stempoint Capital withdrew a net $54.7M in Q2 2026, closing 32 positions and reducing 30 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $28.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Stempoint Capital opened a new position in First Tracks Biotherapeutics worth $12.5M.

  • Stempoint Capital's largest Q2 2026 buy was First Tracks Biotherapeutics: 622,723 shares worth $12.5M.
  • Stempoint Capital added most to Tango Therapeutics in Q2 2026, an estimated $25.3M increase.
  • Stempoint Capital's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $38.5M.
  • Stempoint Capital fully exited Syndax Pharmaceuticals in Q2 2026, selling an estimated $28.4M.
  • Stempoint Capital's ten largest holdings make up 41% of its $581M portfolio in Q2 2026.
  • Stempoint Capital opened 34 new positions and closed 32 in Q2 2026.
  • Stempoint Capital's portfolio value rose 11% quarter-over-quarter to $581M.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.